Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care
Several pharmaceutical companies are developing the Checkpoint Kinase Inhibitors as one of the most promising therapies owing to the treatment of Cancer and Advanced solid tumors.
DelveInsight’s ‘Checkpoint Kinase Inhibitor Pipeline Insights’ report lays out a complete view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Checkpoint Kinase Inhibitor landscape.
Some of the key highlights of the Checkpoint Kinase Inhibitor Pipeline report:
- Checkpoint Kinase Inhibitor Pipeline report offers a detailed analysis of 10+ key players and 10+ key pipeline therapies.
- Checkpoint Kinase Inhibitor pipeline comprises SRA737 (Sierra Oncology), PHI 101 (Pharos I&BT), BI 765063 (Boehringer Ingelheim), V158411 (Vernalis), SOL-578 (Sentinel Oncology) and several others in different stages of clinical trials.
- SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1) being developed by Sierra Oncology. The drug has recently completed two Phase I/II clinical trials for the treatment of Advanced Solid tumor.
- Drug discovery activities at Vernalis and with collaborators have generated V158411 and VER250840, Checkpoint Kinase 1 inhibitors as pre-clinical candidates.
Got queries? Want to know more? Request for Sample @ Checkpoint Kinase Inhibitor Emerging Therapies and Forecast
Checkpoint Kinases
The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage.
Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies.
For more information on Checkpoint Kinase Inhibitors, visit Checkpoint Kinase Inhibitor Pipeline Analysis
Checkpoint Kinase Inhibitor Pipeline Drugs
| Drug | Company | Clinical Phase | RoA |
| SRA737 | Sierra Oncology | I/II | Oral |
| CBP501 | CanBas | I | Intravenous |
| PHI 101 | Pharos I&BT | I | Oral |
| BI 765063 | Boehringer Ingelheim | I | Parenteral |
| Prexasertib | Eli Lilly and Company | I | NA |
| SOL-578 | Sentinel Oncology | Preclinical | NA |
| V158411 | Vernalis | Preclinical | Intravenous |
| Research Programme: Checkpoint Kinase Inhibitors | Pink Biopharma | Discovery | NA |
| IMP 10 | IMPACT Therapeutics | Discovery | NA |
Request for Sample to know more @ Checkpoint Kinase Inhibitor Pipeline Analysis, Key Companies and Futuristic Trends
Checkpoint Kinase Inhibitor Therapeutic Assessment
The Checkpoint Kinase Inhibitor Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
By Stage and Route of Administration
By Stage and Product Type
Get in touch with our Business executive for Drug Pipeline Assessment and Consulting Solutions
Scope of the Report
Coverage: Global
Key Players: Boehringer Ingelheim, CanBas, Vernalis, Sierra Oncology, Pharos I&BT Co, Eli Lilly and company, Sentinel Oncology, IMPACT Therapeutics, Pink Biopharma.
Key Checkpoint Kinase Inhibitor Pipeline Therapies: BI 765063, CBP501, VER-250840, SRA737, PHI-101, Prexasertib, SOL 578, IMP10, and Research Programme: checkpoint kinase inhibitors.
Reach out @ Checkpoint Kinase Inhibitor Pipeline: Novel therapies and Emerging Technologies
Key Questions Answered in the Report
- What are the current treatment options available based on the Checkpoint Kinase Inhibitor?
- How many companies are developing therapies by working on Checkpoint Kinase Inhibitor?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for Checkpoint Kinase Inhibitors to treat disease conditions?
- How many emerging therapies are in the early-stage, mid-stage, and late stage of development for Checkpoint Kinase Inhibitor?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-? Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Checkpoint Kinase Inhibitor therapies?
Request for Webex demo of the report @ Checkpoint Kinase Inhibitor Pipeline Analysis and Emerging Trends
Table of Contents
| 1 | Introduction |
| 2 | Checkpoint Kinase Inhibitor Overview |
| 3 | Checkpoint Kinase Inhibitor Pipeline Therapeutic Assessment |
| 4 | Checkpoint Kinase Inhibitor – DelveInsight’s Analytical Perspective |
| 5 | Late Stage Checkpoint Kinase Inhibitor Pipeline Products (Phase III and Preregistration) |
| 6 | Mid-Stage Checkpoint Kinase Inhibitor Pipeline Products (Phase II) |
| 7 | Pre-clinical and Discovery Stage Checkpoint Kinase Inhibitor Pipeline Products |
| 8 | Pre-clinical Products and Discovery Stage Products |
| 9 | Inactive Checkpoint Kinase Inhibitor Pipeline Products |
| 10 | Dormant Checkpoint Kinase Inhibitor Pipeline Products |
| 11 | Discontinued Checkpoint Kinase Inhibitor Pipeline Products |
| 12 | Checkpoint Kinase Inhibitor Key Companies |
| 13 | Checkpoint Kinase Inhibitor Key Products |
| 14 | Checkpoint Kinase Inhibitor Unmet Needs |
| 15 | Checkpoint Kinase Inhibitor Market Drivers and Barriers |
| 16 | Checkpoint Kinase Inhibitor Future Perspectives and Conclusion |
| 17 | Checkpoint Kinase Inhibitor Pipeline Analyst Views |
| 18 | Appendix |
| 20 | Report Methodology |
Visit to know more of what’s covered @ Checkpoint Kinase Inhibitor Emerging Therapies
Related Reports
Global Kinase Inhibitor In Autoimmune Diseases Market
DelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases – Market Insights and Market Forecast – 2030’ report.
Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Market
DelveInsight’s ‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast-2030’ report.
Cyclin-Dependent Kinase Like 5 Cdkl5 Deficiency Disorder Market
DelveInsight's "Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Market Insights, Epidemiology, and Market Forecast-2030" report.
Pyruvate Kinase Deficiency Market
DelveInsight's "Pyruvate Kinase Deficiency - Market Insights, Epidemiology, and Market Forecast-2030" report.
Bruton’s Tyrosine Kinase Btk Inhibitors Competitive Landscape Pipeline And Market Analysis
DelveInsight’s “Bruton's Tyrosine Kinase (BTK) Inhibitors – Competitive Landscape, Market and Pipeline Analysis, 2020” report.
Anaplastic Lymphoma Kinase Inhibitor Pipeline Insight
DelveInsight’s "Anaplastic Lymphoma Kinase (ALK) Inhibitor - Pipeline Insights, 2021" report.
Thymidine Kinase 2 Deficiency Pipeline Insight
DelveInsight’s "Thymidine Kinase 2 Deficiency (TK2D) Pipeline Insights, 2021" report.
AXL Kinase Inhibitor Pipeline Insight
DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2021” report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News